Treatment of common ocular allergic disorders; a comparison of lodoxamide and NAAGA

Denis, D.; Bloch-Michel, E; Vérin, P; Sebastiani, Adolfo; Tazartes, M.; Helleboid, L.; Giovanni, Alfredo Di

doi:10.1136/bjo.82.10.1135

Cited by 13 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nacetylaspartate dipeptide, which suppresses the formation of leukotrienes, histamine from mast cells, and anaphylatoxin produced from complement, has also been demonstrated to be utilised as a topical ocular treatment for VKC and GPC in Europe. 40…”

Section: Mast Cell Stabilizersmentioning

confidence: 99%

A review on pathophysiology and managements of allergic conjunctivitis

Patel,

Chandra,

Sachan

et al. 2024

IJCEO

View full text Add to dashboard Cite

Allergic disorder is a serious issue affecting 40% of the population. The most well-known visual illness in clinical practise is undoubtedly visual sensitivity. The impact of numerous variables, including genetics and pollution, is taken into account by experts. Therefore, this review is intends to provide the detailed description related to pathophysiology and managements of allergic conjunctivitis.The study was performed by literature survey of original research articles published in Pubmed, Science direct, Web of Science, Scopus and Google etc.The two primary types of allergic conjunctivitis are perennial allergic conjunctivitis (PAC) and seasonal allergic conjunctivitis (SAC). The common effects of SAC and PAC are shivers, weeping, mucus production, and redness; nonetheless, these structures do not impair vision. However, vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC) are the most alarming types of visual allergic conjunctivitis, which impact the cornea and can impair vision if not properly recognised and treated. Allergic conjunctivitis symptoms include itchy, stinging red eyes and yellow pus during sleep. The major objectives of treatment for allergic conjunctivitis are to lessen and manage symptoms and raise quality of life. This involves minimising itchiness, as well as redness, tears, edoema of the conjunctiva or the eyelids, and other related disorders. Breaking the pattern of inflammation and reducing it are additional therapy objectives for patients with chronic allergen exposure and persistent illness. Mast cell stabilisers, corticosteroids, antihistamines, NSAIDs, dual-acting antiallergics, anti-leukotrienes, anti-IgE, and some other drugs are used to treat allergic conjunctivitis.There are the different types of allergic conjunctivitis among which the more prevalence types of allergic conjunctivitis are SAC and PAC while the more severe types are VKC and AKC. There are different types of medicines available for treatment of allergic conjunctivitis.

show abstract

Section: Mast Cell Stabilizersmentioning

confidence: 99%

A review on pathophysiology and managements of allergic conjunctivitis

Patel,

Chandra,

Sachan

et al. 2024

IJCEO

View full text Add to dashboard Cite

show abstract

“…NAAGA eye drops are currently marketed in several countries; they were approved in 1984 for treating moderate forms of allergic conjunctivitis. The efficacy and safety of NAAGA eye drops were previously demonstrated in patients with allergic conjunctivitis, including SAC 2–14 . SAC symptoms occur when pollen dissolves in the tear film, then crosses the conjunctiva 15 .…”

Section: Introductionmentioning

confidence: 99%

Efficacy of N‐acetyl aspartyl glutamic acid versus fluorometholone for treating allergic conjunctivitis in an environmental exposure chamber

Blay

Gherasim

Domis

et al. 2022

Clin Experimental Allergy

View full text Add to dashboard Cite

Background Topical mast cell stabilizers were previously shown to treat the signs and symptoms of seasonal and perennial allergic conjunctivitis safely and effectively in active and placebo‐controlled trials. However, mast cell stabilizers have not been compared to topical corticosteroids for efficacy. We tested the non‐inferiority of a topical mast cell stabilizer, N‐acetyl aspartyl glutamic acid (4.9%, NAAGA), compared to fluorometholone (0.1%, FM) during controlled exposures to the airborne birch pollen allergen, Bet v 1, in an environmental exposure chamber (EEC). Methods This randomized, cross‐over, investigator‐blinded study included 24 patients with a history of birch pollen allergic conjunctivitis. Patients were randomized to 5 days of treatment with NAAGA, then FM (n = 12) or FM, then NAAGA (n = 12). After each treatment, patients were exposed to a fixed airborne concentration of Bet v 1 in ALYATEC EEC. The primary endpoint was the amount of allergen required to trigger a conjunctival response (Abelson score ≥5). Groups were compared with a linear model for cross‐over studies. Non‐inferiority was assumed, when the lower bound of the risk ratio confidence interval (CI) was >0.5. Results At screening, the mean time‐to‐conjunctival response was 72.5 ± 35.9 min. NAAGA and FM extended the response time to 114.8 ± 55.0 and 116.6 ± 51.5 min respectively. The mean amounts of allergen required to trigger a conjunctival response were 1.165 ng after NAAGA and 1.193 ng after FM treatment. The risk ratio for the conjunctival response was 0.977 (95% CI: 0.812; 1.174), which indicated non‐inferiority. Adverse events occurred less frequently with NAAGA (29.2%) than with FM (58.3%). Conclusion In patients with allergic conjunctivitis to birch pollen, NAAGA was non‐inferior to FM in exposures to airborne Bet v 1. The EEC was a good model for simulating real‐life airborne allergen exposure and for demonstrating the efficacy and safety of eye drops for treating allergic conjunctivitis. Trial registration Not registered.

show abstract

“…In less severe cases mast cell stabilisers such as disodium cromoglycate, N-acetyl aspartyl glutamic acid and lodoxamide trometamol 0.1% ophthalmic solution ('lodoxamide') may prevent inflammation. Lodoxamide is effective in various forms of non-infective allergic conjunctivitis (3)(4)(5). It has no intrinsic vasoconstrictor, antihistaminic, cyclooxygenase inhibitory, or other anti-inflammatory activity (6).…”

mentioning

confidence: 99%